• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.

作者信息

Greenberg R N, Reilly P M, Weinandt W J, Bollinger M, Kennedy D J

机构信息

Department of Medicine, Saint Louis University School of Medicine, Missouri.

出版信息

Clin Ther. 1987;10(1):52-6.

PMID:3329965
Abstract

Seventy hospitalized patients with upper urinary tract infections were treated with cefoperazone (2 gm) and sulbactam (1 gm) every 12 hours for three or more days. All but six patients also received vitamin K. Forty of the 70 patients (57%) were cured of infection at one week after treatment, 13 relapsed, 11 had reinfections, and six were lost to follow-up. There were no treatment failures. Escherichia coli was the predominant pathogen (62% of isolates). Overall there was 15% resistance to cefoperazone and all resistant isolates were susceptible to the combination of agents. Synergy was demonstrated in 26% of isolates. One uroseptic patient who had an organism resistant to both study agents, but susceptible to the combination, was cured. Two of six patients who did not receive vitamin K demonstrated abnormal coagulation patterns and one had an associated major bleeding complication. Although 12 of 64 (19%) patients who received vitamin K had at least one coagulation abnormality, there were no significant bleeding complications in this group.

摘要

相似文献

1
Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Clin Ther. 1987;10(1):52-6.
2
[Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].舒巴坦/头孢哌酮(SBT/CPZ)治疗细菌性前列腺炎的实验室与临床研究
Hinyokika Kiyo. 1991 Oct;37(10):1333-43.
3
[Clinical study on sulbactam/cefoperazone in urinary tract infections in elderly patients].舒巴坦/头孢哌酮治疗老年患者尿路感染的临床研究
Jpn J Antibiot. 1996 Mar;49(3):250-5.
4
Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.舒巴坦/头孢哌酮与头孢噻肟治疗中重度细菌感染:一项随机对照临床试验的结果
Clin Infect Dis. 1997 Mar;24(3):498-505. doi: 10.1093/clinids/24.3.498.
5
In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.头孢哌酮-舒巴坦组合对马来西亚一家综合医院中耐头孢哌酮临床分离株的体外活性
Malays J Pathol. 1995 Dec;17(2):73-6.
6
Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.头孢菌素治疗产CTX-M型超广谱β-内酰胺酶大肠埃希菌所致菌血症的疗效
Diagn Microbiol Infect Dis. 2006 Dec;56(4):351-7. doi: 10.1016/j.diagmicrobio.2006.06.015. Epub 2006 Aug 23.
7
[Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].[应用抑制剂保护的第三代头孢菌素头孢哌酮/舒巴坦治疗严重医院感染的临床经验]
Antibiot Khimioter. 2005;50(4):33-40.
8
A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.头孢曲松/舒巴坦与头孢哌酮/舒巴坦治疗呼吸道和尿路感染的多中心临床研究。
Ann Clin Microbiol Antimicrob. 2013 Dec 9;12:38. doi: 10.1186/1476-0711-12-38.
9
Urinary tract infection in women over the age of 65: is age alone a marker of complication?65岁以上女性的尿路感染:仅年龄就是并发症的一个标志吗?
J Am Board Fam Med. 2009 May-Jun;22(3):266-71. doi: 10.3122/jabfm.2009.03.080123.
10
Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.从土耳其社区获得性尿路感染中分离出的大肠杆菌菌株对环丙沙星耐药的危险因素。
J Antimicrob Chemother. 2005 Nov;56(5):914-8. doi: 10.1093/jac/dki344. Epub 2005 Sep 20.

引用本文的文献

1
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.攻克外膜:促进化合物进入革兰氏阴性菌病原体。
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
2
Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses.头孢哌酮-舒巴坦致埃及重症患者凝血障碍:维生素K预防剂量的作用
Hosp Pharm. 2024 Oct;59(5):575-583. doi: 10.1177/00185787241238310. Epub 2024 Mar 13.
3
Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
头孢哌酮/舒巴坦所致凝血功能障碍的危险因素
Infect Drug Resist. 2023 Sep 21;16:6277-6284. doi: 10.2147/IDR.S429706. eCollection 2023.
4
Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.替加环素联合头孢哌酮/舒巴坦治疗与其他基于替加环素的联合治疗之间出血风险及低纤维蛋白原血症相关危险因素的比较。
Front Pharmacol. 2023 Jun 7;14:1182644. doi: 10.3389/fphar.2023.1182644. eCollection 2023.
5
Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature.头孢哌酮/舒巴坦致腹壁血肿及上消化道出血:1例病例报告并文献复习
Drug Saf Case Rep. 2016 Dec;3(1):2. doi: 10.1007/s40800-016-0025-9.